Pharmaceutical manufacturers are fined and may also be liable for damages
Servier and other French pharmaceutical manufacturers have received fines and are potentially open to claims for damages for conspiring to keep generic medicines off the market.
The European Commission has imposed fines totalling €427.7m (£340m) on French pharmaceutical company Servier and five producers of generic medicines for concluding a series of deals all aimed at protecting Servier’s bestselling blood-pressure medicine, perindopril, from price competition by generics in the EU.
Servier was found to have had a strategy of systematically buying out any competitive threats to make sure that they stayed out of the market. The European Commission found that such behaviour was clearly anti-competitive and abusive. Servier’s overall strategy was found to be contrary to article 102 of the Treaty on the Functioning of the European Union (TFEU), while the individual agreements with the generic manufacturers were contrary to article 101 TFEU…
Click on the link below to read the rest of the LK Shields Solicitors briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from LK Shields Solicitors
News from The Lawyer
Briefings from LK Shields Solicitors
It is now an offence if minutes of board meetings are not recorded and retained.
All S.110 companies will be brought within the scope of quarterly reporting obligations.